These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2224165)

  • 1. [Adoptive immunotherapy with interleukin 2 in oncology].
    Favrot M; Bouffet E; Négrier S; Combaret V; Philip I; Philip T
    Bull Cancer; 1990; 77(9):925-31. PubMed ID: 2224165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.
    Favrot MC; Floret D; Negrier S; Cochat P; Bouffet E; Zhou DC; Franks CR; Bijman T; Brunat-Mentigny M; Philip I
    Bone Marrow Transplant; 1989 Sep; 4(5):499-503. PubMed ID: 2790327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment with cytokines of metastatic kidney cancer: the Lyon experience].
    Négrier S; Mercatello A; Coronel B; Lanier F; Merrouche Y; Bret M; Blay JY; Lasset C; Thiesse P; Carrie C
    Bull Cancer; 1993 Jul; 80(7):601-9. PubMed ID: 8204940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
    Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
    Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies.
    Rueda F; Martí F; Pardo N; Badell I; Peiró M; Bertran E; Villén E; García J; Cubells J
    Cancer Biother Radiopharm; 1996 Oct; 11(5):303-8. PubMed ID: 10851509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
    Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M
    Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
    Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
    Kimura H; Yamaguchi Y
    Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.
    Wang JC; Walle A; Novogrodsky A; Suthanthiran M; Silver RT; Bander NH; Rubin AL; Stenzel KH
    J Clin Oncol; 1989 Dec; 7(12):1885-91. PubMed ID: 2555451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.
    Blay JY; Favrot MC; Negrier S; Combaret V; Chouaib S; Mercatello A; Kaemmerlen P; Franks CR; Philip T
    Cancer Res; 1990 Apr; 50(8):2371-4. PubMed ID: 2317822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of renal cancer in adults with interleukin 2].
    Negrier S; Mercatello A; Philip T
    Rev Prat; 1992 May; 42(10):1241-5. PubMed ID: 1609217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma.
    Negrier S; Michon J; Floret D; Bouffet E; Gentet JC; Philip I; Cochat P; Stamm D; Costil J; Gaspard M
    J Clin Oncol; 1991 Aug; 9(8):1363-70. PubMed ID: 1830096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
    Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
    Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia].
    Parrado A; Casares S; Carmona M; Campo T; Rodríguez Fernández JM
    Sangre (Barc); 1994 Oct; 39(5):393-6. PubMed ID: 7754446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.